Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health will implement a 1-for-60 reverse stock split of its common stock on May 23, 2024, following approval at the April 2024 Special Meeting of Stockholders. The split aims to support compliance with Nasdaq listing standards and attract institutional investors. Post-split, the stock will trade under the symbol JAGX with a new CUSIP number: 47010C805. Fractional shares will be settled in cash.
Equiniti Trust Company will handle the exchange process for stockholders holding certificates. No action is required for those with shares in brokerage accounts.
Jaguar Health (NASDAQ:JAGX) reported a 20% increase in net revenue for Q1 2024, amounting to $2.4 million compared to $2.0 million in Q1 2023, and a 4% increase from Q4 2023. The company is set to release top-line results from its Phase 3 OnTarget trial for crofelemer, aimed at treating cancer therapy-related diarrhea. A commercial launch for the FDA-approved oral mucositis product Gelclair is planned for Q3 2024. Despite a reduction in Mytesi prescription volumes, the company achieved a net loss reduction of 24%, equating to $9.2 million, compared to $12.2 million in Q1 2023. Operational loss decreased by 17%, from $9.8 million to $8.2 million, due to reductions in R&D, sales, marketing, and administrative expenses. However, the overall cost of product revenue increased slightly.
Jaguar Health, Inc. (NASDAQ: JAGX) will hold an investor webcast on May 14, 2024, to discuss Q1 2024 financials and corporate updates.
Jaguar Health announced the submission of Clinical Trial Applications for Crofelemer for the rare disease indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe. The novel plant-based prescription drug Crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS. Clinical Trial Applications have been submitted to Italian and German health authorities for a phase 2 clinical trial for the treatment of SBS in adults and to AIFA in Italy for a trial in pediatric patients with MVID. The company aims to develop a novel powder formulation of Crofelemer for oral solution to help patients with these devastating rare diseases. Proof-of-concept results are expected in 2024 in the US, EU, and MENA regions.
Jaguar Health, Inc. (NASDAQ: JAGX) will hold an investor webcast on May 14, 2024, to discuss Q1 2024 financials and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ended March 31, 2024.
Jaguar Health's prescription drug crofelemer, approved by the FDA for chemotherapy-induced diarrhea in dogs, is now being investigated for the treatment of general diarrhea in dogs. The company aims to address the unmet need for FDA-approved anti-secretory agents for canine diarrhea.
Jaguar Health, Inc. announced that its subsidiary Napo Pharmaceuticals is sponsoring a Pediatric Gastroenterology Conference in Abu Dhabi and a panel discussion on Microvillus Inclusion Disease. The company's drug crofelemer has Orphan Drug Designation for MVID and short bowel syndrome (SBS). Proof-of-concept studies for these diseases are planned for 2024. The FDA activated Napo's IND application for a phase 2 trial of crofelemer for pediatric MVID patients, with results expected in 2024. MVID is a severe infantile disease with no approved treatments. Leading experts in MVID treatment will participate in the panel discussion.
Summary not available.
Summary not available.
Summary not available.